The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Takeda
Stock and Other Ownership Interests - Takeda
Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B-cell lymphomas.
 
Deepa Jagadeesh
Research Funding - Debiopharm Group (Inst); MEI Pharma (Inst); Regeneron (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst)
 
Steven M. Horwitz
Consulting or Advisory Role - ADC Therapeutics; Celgene; Corvus Pharmaceuticals; Innate Pharma; Kyowa Hakko Kirin; Millennium; miRagen; Portola Pharmaceuticals; Seagen; Takeda; Verastem
Research Funding - ADC Therapeutics; Aileron Therapeutics; Celgene; Forty Seven; Kyowa Hakko Kirin; Seagen; Takeda; Verastem
 
Nancy L. Bartlett
Consulting or Advisory Role - ADC Therapeutics; Pfizer; Seagen
Research Funding - Affimed Therapeutics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Forty Seven (Inst); Genentech (Inst); Gilead Sciences (Inst); Immune Design (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Merck (Inst); Millennium (Inst); Pharmacyclics (Inst); Seagen (Inst)
 
Ranjana H. Advani
Consulting or Advisory Role - AstraZeneca; Autolus; Bayer; Bristol-Myers Squibb; Cell Medica; Genentech/Roche; Gilead Sciences; Pharmacyclics; Seagen; Takeda
Research Funding - Agensys (Inst); Celgene (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Infinity Pharmaceuticals (Inst); Janssen (Inst); Kura Oncology (Inst); Merck (Inst); Millennium (Inst); Pharmacyclics (Inst); Regeneron (Inst); Seagen (Inst)
 
Eric D. Jacobsen
Consulting or Advisory Role - Janssen; Merck; Seagen
Research Funding - Celgene
Travel, Accommodations, Expenses - Merck
 
Madeleine Duvic
Leadership - Aclaris Therapeutics; Celgene; Forty Seven; Kyowa Hakko Kirin; Mallinckrodt; Medivir; Millenium Pharamceuticals; Precision Oncology; Seagen; Soligenix
Honoraria - Aclaris Therapeutics; Array BioPharma; Celgene; Cell Medica; Kyowa Hakko Kirin; Mallinckrodt; Millenium Pharamceuticals; Seagen
Consulting or Advisory Role - Array BioPharma; Celgene; Cell Medica; Clinical Care Options/NCCN; Concert Pharmaceuticals; Defined Health; Dr. Reddy's; Evidera; Guidepoint Global; Huron Consulting; HUYA Bioscience International; Kiniksa; Lynx Group; MedaCorp; miRagen; Taiwan Liposome
Speakers' Bureau - Jonathan Wood and Associates; Medscape
Research Funding - Allos Therapeutics; Eisai; Kyowa Hakko Kirin; Mallinckrodt; MPI Research; Oncoceutics; Rhizen Pharmaceuticals; Seagen; Shape Pharmaceuticals; Soligenix; TetraLogic Pharmaceuticals
 
Ashish Gautam
No Relationships to Disclose
 
Shangbang Rao
Employment - Bristol-Myers Squibb; Seagen
Stock and Other Ownership Interests - Seagen
 
Matthew Onsum
Employment - Seagen; Seagen
Stock and Other Ownership Interests - Seagen
 
Michelle Fanale
Employment - Seagen
Stock and Other Ownership Interests - Seagen
Honoraria - Bristol-Myers Squibb; Merck; Spectrum Pharmaceuticals; Takeda
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Merck
Research Funding - ADC Therapeutics; Bristol-Myers Squibb; Genentech; Gilead Sciences; MedImmune; Merck
 
Youn H. Kim
Consulting or Advisory Role - Actelion; Eisai; Innate Pharma; Kyowa Hakko Kirin; Medivir; Millennium; miRagen; Seagen
Research Funding - Eisai (Inst); Forty Seven (Inst); Horizant (Inst); Innate Pharma (Inst); Kyowa Hakko Kirin (Inst); Merck (Inst); Millennium (Inst); miRagen (Inst); miRagen (Inst); Neumedicines (Inst); Portola Pharmaceuticals (Inst); Seagen (Inst); Soligenix (Inst)
Patents, Royalties, Other Intellectual Property - Royalty for Chapters in UpToDate
Travel, Accommodations, Expenses - Innate Pharma